HPV Testing: Market Research Report

January 2015 | 242 pages | ID: HCA569BED23EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for HPV Testing in US$ Thousand. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 43 companies including many key and niche players such as -

• Abbott Molecular, Inc.
• Arbor Vita Corporation
• Becton, Dickinson and Company
• DaAn Gene Co., Ltd.
• F. Hoffmann-La Roche Ltd.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

HPV Testing Market – Quick Facts
Global HPV Testing Market: A Prelude
Current and Future Analysis
List of Select HPV Molecular Diagnostic Tests by Company and Technique
Cervical Cancer: Rising Incidence & Mortality Enhances Need for Testing
Major Risk Factors to HPV/Cervical Cancer

Table 1. Number of New Cervical Cancer Cases in the World by Region and Age Group (2012) (includes corresponding Graph/Chart)

Table 2. World Age-Standardized Cervical Cancer Incidence Rates (2012): Breakdown by Region (includes corresponding Graph/Chart)

Table 3. Worldwide Cervical Cancer Mortality by Leading Countries (2012): Ranked by Number of Deaths (in ‘000s) (includes corresponding Graph/Chart)

HPV Testing for Primary Screening Indication Bodes Well for the Market’s Growth

Table 4. Cervical Screening Penetration in Select Countries (2012): % of Women in 20-69 Age Group Screened for Cervical Screening(includes corresponding Graph/Chart)

Developing Markets to Drive Global Growth

Table 5. Number of HPV Tests by Geographic Region (2012) (In Million) (includes corresponding Graph/Chart)

Table 6. Global HPV Testing Market by Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Normal Cytology (includes corresponding Graph/Chart)

Table 7. Global HPV Testing Market by Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Cervical Cancer (includes corresponding Graph/Chart)C Countr

Table 8. Global HPV Testing Market by Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Low-Grade Lesions (includes corresponding Graph/Chart)mas Card

Table 9. Global HPV Testing Market by Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with High-Grade Lesions (includes corresponding Graph/Chart)ndian 14Latest Developments in HPV Testing Promise Bright Future Ahead

Reimbursement Coverage Influences Adoption of HPV Testing
HPV Vaccination Programs: Assessing the Impact on HPV Testing Market
Some of the most common and rare side effects include:
Gardasil - A Biohazard?
Side-effects of Gardasil More Apparent among Preteens
Inhalable Cervical Cancer Vaccines to Grow in Popularity
HPV Vaccine Proves Beneficial in Prevention of Genital Warts in Men
HPV Vaccination Initiatives in Select Countries
HPV Vaccine Implementation: HPV Immunization Schedule and Population Coverage by Country

2. COMPETITIVE LANDSCAPE

Qiagen, the Global Leader Face Headwinds from Roche

Table 10. Assessing the Impact of FDA’s Approval of Roche’s HPV Test on HPV Sales of Market Majors: Y-O-Y Quarterly HPV Sales Growth for QIAGEN, Hologic and Rochea D90 Ha

Table 11. Leading Players in the Global HPV Testing Market (2014E): Percentage Share Breakdown of Revenues for Abbott, Becton Dickinson, Hologic/Gen-probe, QIAGEN, Roche, and Others (includes corresponding Graph/Chart)r PaaS SComparative Analysis of HPV Testing Products

A Review of Select HPV Tests
digene HC2 HPV DNA Test
digene HC2 High-Risk HPV DNA Test
careHPV Test
Cervista HPV HR Test
Cervista HPV 16/18 Test
Cobas 4800 HPV test
Aptima HPV Assay

3. MARKET DYNAMICS

HPV Testing: A Fast Growing Segment in the STD Diagnostic Testing Market
Pap Cytology and HPV Co-testing: Improved Determination of Cervical Cancer Risk
Cervical Cytology Screening: An Abstract
Conventional Pap Smear Tests Give Way to Liquid-based Cytology Tests

Table 12. Pap Tests Market in Select Countries (2014E): Percentage Share Breakdown of Number of Tests by Conventional Cytology Tests and Liquid-based Cytology Tests (includes corresponding Graph/Chart) Remains

Table 13. Pap Smear Tests by Geography (2014E): Percentage Breakdown by Number of Tests for US, EU and Asia & Latin America (includes corresponding Graph/Chart)t of HeaNon-Invasive Urine HPV Test Holds Potential to Replace Pap Smear Test

Cervical Cancer Screening: Focus on Detection of CIN2 and CIN3 Cancers
Regular HPV Screening Enhances Treatment and Survival Options
Need for Genotyping of HPV Subtypes Beyond 16 &
Detecting E6 and E7 Oncoproteins to Improve Efficacy of Cervical Cancer Screening
Novel Technological Developments to Enhance Accuracy of Screening Procedures
Use of Non-FDA Approved Tests for HPV Testing: A Major Concern
Increase in Instances of HPV-Linked Oral Cancer – A Cause of Deep Concern
Research Findings Indicate Two Vaccination Doses Equal Three
Men Found to be More Susceptible to Oral HPV Infections

4. REGULATORY LANDSCAPE

Favorable Guidelines: A Key Growth Driving Factor
Recommendations of Interim Guidance Report Issued by SGO and ASCCP: Jan 2015
Capitulation of Cervical Cancer Screening Guidelines (2009-2012)
Revised Guidelines for Cervical Cancer Screening: 2012
HPV Test to be a Part of the New Cervical Cancer Screening Guidelines in the US
US Government Proposes Administration of HPV Vaccine for Males

5. OVERVIEW OF CYTOLOGY AND HPV TESTING

What is HPV?
Types of HPV
Commonly Known Diseases and Related HPV Test Types
Common Types of HPV Diseases
Lung Cancer
Cutaneous HPVs
Genital HPVs
Throat Cancer
Causes of Infection
Cervical Cancer and HPV
HPV and Other Cancers
Techniques for Detecting HPV
Signal-Amplified Nucleic Acid Assays
Target-Amplified HPV Assays
What is HPV Testing?
Test of HPV in Men
Test of HPV in Women
HPV Test Results
Limitations of HPV Testing
Advantages of HPV Testing
Cervical Cytology Observation/Screening
Pap Smear Screening
Requirements for Pap Smear Test
Advantages of Pap smear Test
Limitations of Cytologic Screening
HPV Testing vs. Cytology Testing

6. PRODUCT INTRODUCTIONS/APPROVALS

Abbott Introduces RealTime High Risk HPV Test
Advanced Cell Diagnostics to Introduce HPV Assay Based on RNAscope Technology
Roche Receives US FDA Approval for cobas HPV Test for First-Line Primary Screening for Cervical Cancer in Women
Cepheid Releases Xpert HPV Test for Cervical Cancer-Related HPV
Qiagen Introduces careHPV Test in India
BD Diagnostics Gains CE/IVD Marking for BD Onclarity HPV Assay
Hologic Gains FDA Approval for Aptima HPV 16 18/45 Genotype Assay
QIAGEN Launches careHPV Test in China
Roche Seeks Initial Screening Indication for Cobas HPV Test
Hologic Secures Approval for Aptima HPV Assay from US FDA
Cancer Genetics Introduces FHACT Test
CureHealth Diagnostics Unveils New HPV Detection Technology in India
Abbott Rolls Out RealTime High Risk HPV Test in Canada
Trovagene Launches HPV-HR Test
Hologic Bags FDA Approval for Using APTIMA HPV 16 18/45 Genotype Assay with TIGRIS System
FDA Grants Approval for Gen-Probe's PANTHER System
GenPath Women's Health Rolls Out GenCerv HPV Test
Seegene Unveils QuantPlex HPV28 Genotyping Assay
QIAGEN Launches QIAensemble Decapper Sample Preparation Automation System in Europe

7. RECENT INDUSTRY ACTIVITY

Cancer Genetics Acquires BioServe India
Arbor Vita Enters into Distribution Agreement with AB ANALITICA
Australian MSAC Recommends HPV Testing as Primary Cervical Cancer Screening Tool
CytoCore Announces Name Change to MEDITE Cancer Diagnostics
Enzo Ties up with IncellDx Inc
IncellDx Inks Agreement with GeneCell Diagnostics
IncellDx and Kindstar Global Ink Agreement
Quest Diagnostics and Hologic Enter into Strategic Alliance
QIAGEN and Calmette Hospital Enter into Partnership
Hologic Acquires Gen-Probe
QIAGEN Enters into Co-Marketing Agreement with KingMed Diagnostics
Gynecor Implements cobas 4800 Analyzer for HPV Test
Molecular Pathology Laboratory Network to Adopt Hologic/Gen-Probe APTIMA HPV Assay
Trovagene Inks Agreement with Strand Life Sciences
Bio-Reference Laboratories Acquires Stake in InCellDx
QIAGEN Inks Co-Marketing Agreement with KingMed Diagnostics
Roche Signs Agreement with Unilabs-IHS to Expand Access to HPV Testing in UK

8. FOCUS ON SELECT GLOBAL PLAYERS

Abbott Molecular, Inc. (US)
Arbor Vita Corporation (US)
Becton, Dickinson and Company (US)
DaAn Gene Co. , Ltd. (China)
F. Hoffmann-La Roche Ltd. (Switzerland)
Hologic, Inc. (US)
QIAGEN N. V. (The Netherlands)
Seegene, Inc. (South Korea)

9. GLOBAL MARKET PERSPECTIVE

Table 14. World Recent Past, Current and Future Analysis for HPV Testing by Geographic Region/ Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)

High Mo

Table 15. World Historic Review for HPV Testing by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)

Table 16. World 12-Year Perspective for HPV Testing by Geographic Region/Country - Percentage Breakdown of Revenues for US, Japan, Europe, and Rest of World Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market Analysis
Cervical Cancer in the US – Key Statistics & Findings

Table 17. Key Facts on Cervical Cancer in the US: 2014

Table 18. Prevalence of HPV in the US by Age (includes corresponding Graph/Chart)

Table 19. Prevalence of HPV16 and HPV18 in the US by Cytology (2014) (includes corresponding Graph/Chart)

Table 20. Number of New Cervical Cancer Cases by US State (2015)

Table 21. Incidence and Mortality Rate of Cervical Cancer by Ethnicity in the US (2007-2011) (includes corresponding Graph/Chart)

HPV Testing Market – A Review

Table 22. Cervical Cancer by HPV Type (2014E): Percentage Share Breakdown of Cervical Cancer Cases by HPV Type (includes corresponding Graph/Chart)

Use of Non-FDA Approved Tests for HPV Testing: A Major Concern
Competitive Landscape

Table 23. Leading Players in the US HPV Testing Market (2013): Percentage Share Breakdown of Revenues for Hologic, QIAGEN, and Others (includes corresponding Graph/Chart)

Cytology Testing Market – An Insight

Table 24. Pap Tests Market in the US (2014E): Percentage Share Breakdown of Number of Tests by Conventional Cytology Tests and Liquid-based Cytology Tests (includes corresponding Graph/Chart)

HPV Vaccine Implementation
Reimbursement of Screening Procedures
Regulatory Landscape
Recommendations of Interim Guidance Report Issued by SGO and ASCCP: Jan 2015
Overview of Cervical Cancer Screening Guidelines
Revised Guidelines for Cervical Cancer Screening: 2012

2011: US GOVERNMENT PROPOSES ADMINISTRATION OF HPV VACCINE FOR MALES

HPV Vaccine Implementation in the US Sates
HPV Vaccines Legislations Passed by Individual US States (2011-2012)
Product Introductions/Approvals
Strategic Corporate Developments
Key Players
B. Market Analytics

Table 25. US Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 26. US Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)

2. JAPAN

A. Market Analysis
Outlook
Key Statistics in a Nutshell

Table 27. Cervical Cancer in Japan (2014E): Percentage Share Breakdown of New Cases and Number of Deaths by Age Group (includes corresponding Graph/Chart)

Table 28. Crude HPV Prevalence (%) in Women with Normal Cytology by Age Group (2014) (includes corresponding Graph/Chart)

Table 29. Japanese HPV Market (2012): Leading HPV Types Causing Cervical Cancer (includes corresponding Graph/Chart)

Japan Discontinues Recommendation of FDA Approved HPV Drugs
B. Market Analytics

Table 30. Japanese Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 31. Japanese Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)

3. EUROPE

A. Market Analysis
Outlook
Cervical Cancer Screening in Europe – A Review

Table 32. Key Facts on Cervical Cancer in Europe: 2014 (includes corresponding Graph/Chart)

Table 33. Estimated New Cervical Cancer Cases per Year in Europe by Region and Age Group: 2012 (includes corresponding Graph/Chart)

Table 34. Number of Deaths due to Cervical Cancer per Year in Europe by Region and Age Group: 2012 (includes corresponding Graph/Chart)

Table 35. HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Normal Cytology (includes corresponding Graph/Chart)

Table 36. HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Low-Grade Lesions (includes corresponding Graph/Chart)

Table 37. HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with High-Grade Lesions (includes corresponding Graph/Chart)

Table 38. HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Cervical Cancer (includes corresponding Graph/Chart)

Table 39. Cervical Cancer Incidence and Mortality in European Countries (2012) (includes corresponding Graph/Chart)

Table 40. Prevalence of Cervical Cancer in European Countries (2012) (includes corresponding Graph/Chart)

Increasing Effectiveness of Cervical Cancer Screening Programs
Need for Repeat Testing
HPV – The Preferred Primary Screening for Cervical Cancer in Europe
Product Introductions/Approvals
B. Market Analytics

Table 41. European Recent Past, Current and Future Analysis for HPV Testing by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 42. European Historic Review for HPV Testing by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)

Table 43. European 12-Year Perspective for HPV Testing by Geographic Region/Country - Percentage Breakdown of Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2009, 2015 and 2020 (includes corresponding Graph/Chart)

3A. FRANCE

A. Market Analysis
Outlook
Cervical Cancer in France – A Review

Table 44. Key Facts on Cervical Cancer in France: 2014

Table 45. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)

HPV Vaccine Implementation
B. Market Analytics

Table 46. French Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 47. French Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)

3B. GERMANY

A. Market Analysis
Outlook
Cervical Cancer in Germany – A Review

Table 48. Key Facts on Cervical Cancer in Germany: 2014

Table 49. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)

B. Market Analytics

Table 50. German Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 51. German Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)

3C. ITALY

A. Market Analysis
Outlook
Cervical Cancer in Italy – A Review

Table 52. Key Facts on Cervical Cancer in Italy: 2014

Table 53. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)

Strategic Corporate Development
B. Market Analytics

Table 54. Italian Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 55. Italian Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)

3D. THE UNITED KINGDOM

A. Market Analysis
Market Overview
Cervical Cancer – Key Statistics

Table 56. Key Facts on Cervical Cancer in the UK: 2014

Table 57. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)

Impact of HPV Vaccine Implementation
Strategic Corporate Development
B. Market Analytics

Table 58. UK Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 59. UK Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)

3E. REST OF EUROPE

A. Market Analysis
Outlook
Spain

Table 60. Cervical Cancer in Spain (2012): Percentage Share Breakdown of New Cases by Age-Group (includes corresponding Graph/Chart)

Table 61. Key Facts on Cervical Cancer in Spain: 2014

Table 62. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)

Sweden

Table 63. Key Facts on Cervical Cancer in Sweden: 2014

Table 64. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)

The Netherlands

Table 65. Key Facts on Cervical Cancer in the Netherlands: 2014

Table 66. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)

Russia

Table 67. Key Facts on Cervical Cancer in Russia: 2014

Table 68. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)

Strategic Corporate Developments
Key Players
B. Market Analytics

Table 69. Rest of Europe Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 70. Rest of Europe Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)

4. REST OF WORLD

A. Market Analysis
Outlook
Focus on Select Markets
Canada
The Canadian Task Force on Preventive Health Care (CTFPHC) Recommendations for Cervical Cancer Screening: 2013

Table 71. Key Facts on Cervical Cancer in Canada: 2014

Table 72. Estimated Age-Standardized Incidence Rates of Cervical Cancer per 100,000 Women Population in Canada by Province (2014) (includes corresponding Graph/Chart)

Table 73. Estimated Age-Standardized Mortality Rates of Cervical Cancer per 100,000 Women Population in Canada by Province (2014) (includes corresponding Graph/Chart)

Table 74. Prevalence of HPV16 and HPV18 among Women in Canada by Cytology (2014) (includes corresponding Graph/Chart)

Asia-Pacific

Table 75. Key Facts on Cervical Cancer in Asia by Region: 2012 (includes corresponding Graph/Chart)

Table 76. Incidence of Cervical Cancer in Asia by Region: 2012 (includes corresponding Graph/Chart)

Table 77. Estimated New Cervical Cancer Cases per Year in Asia by Region and Age Group: 2012 (includes corresponding Graph/Chart)

Table 78. Number of Deaths due to Cervical Cancer per Year in Asia by Region and Age Group: 2012 (includes corresponding Graph/Chart)

Table 79. HPV Testing Market in Asia by Region (2014): Breakdown by Number of Women Tested with Normal Cytology (includes corresponding Graph/Chart)

Table 80. HPV Testing Market in Asia by Region (2014): Breakdown by Number of Women Tested with Low-Grade Lesions (includes corresponding Graph/Chart)

Table 81. HPV Testing Market in Asia by Region (2014): Breakdown by Number of Women Tested with High-Grade Lesions (includes corresponding Graph/Chart)

Table 82. HPV Testing Market in Asia by Region (2014): Breakdown by Number of Women Tested with Cervical Cancer (includes corresponding Graph/Chart)

China
Introduction

Table 83. Key Facts on Cervical Cancer in China: 2014

Table 84. Prevalence of HPV16 and HPV18 in China by Cytology (2014) (includes corresponding Graph/Chart)

New Testing Technologies Gain Traction
Competitive Landscape

Table 85. Leading Players in China’s HPV Market (2012): Percentage Share Breakdown of Value for Digene, Kaipu, Yaneng, Mingyuan and Others (includes corresponding Graph/Chart)

India
HPV Testing – A Nascent Market

TABLE 86: HPV Prevalence by Histology (includes corresponding Graph/Chart)

Table 87. Prevalence of HPV Types 16 and 18 among Women in India - Breakdown by Cytology (includes corresponding Graph/Chart)

Table 88. Top 10 HPV Oncogenic Types among Women in India (2012): Breakdown of Prevalence (%) by Cytology

Table 89. Most Common HPV Oncogenic Types among Women with Invasive Cancer in India (2012): Breakdown of Prevalence (%) by Histology

Cervical Cancer Screening in India - Still a Long Way to Go

Table 90. Key Facts on Cervical Cancer in India: 2012

Table 91. Cervical Cancer Incidence and Mortality in India: 2012

Table 92. Estimated New Cervical Cancer Cases Per Year by Age Group in India (As of 2012) (includes corresponding Graph/Chart)

Table 93. Number of Deaths due to Cervical Cancer per Year by Age Group in India (As of 2012) (includes corresponding Graph/Chart)

Table 94. Crude Incidence Rate of Most Common Cancers among Women of all Ages in India: 2012 (includes corresponding Graph/Chart)

Table 95. Crude Mortality Rate of Most Common Cancers among Women of all Ages in India: 2012 (includes corresponding Graph/Chart)

Australia

Table 96. Key Facts on Cervical Cancer in Australia: 2014

Table 97. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)

National Cervical Screening Program Continues to Taste Success
Cervarix and Gardasil to Combat Cervical Cancer
New Zealand

Table 98. Key Facts on Cervical Cancer in New Zealand: 2014

Table 99. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology

Latin America

Table 100. Latin America HPV Testing Market by Select Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Normal Cytology (includes corresponding Graph/Chart)

Table 101. Latin America HPV Testing Market by Select Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Low-Grade Lesions (includes corresponding Graph/Chart)

Table 102. Latin America HPV Testing Market by Select Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with High-Grade Lesions (includes corresponding Graph/Chart)

Table 103. Latin America HPV Testing Market by Select Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Cervical Cancer (includes corresponding Graph/Chart)

Brazil

Table 104. Key Facts on Cervical Cancer in Brazil: 2014

Table 105. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)

Mexico

Table 106. Key Facts on Cervical Cancer in Mexico: 2014

Table 107. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)

Africa

Table 108. Key Facts on Cervical Cancer in Africa: 2014

Table 109. HPV Testing Market in Africa by Region (2014): Breakdown by No. of Women Tested and Prevalence of HPV 16/18 in Women with Normal Cytology (includes corresponding Graph/Chart)

Table 110. HPV Testing Market in Africa by Region (2014): Breakdown by No. of Women Tested and Prevalence of HPV 16/18 in Women with Low-Grade Lesions (includes corresponding Graph/Chart)

Table 111. HPV Testing Market in Africa by Region (2014): Breakdown by No. of Women Tested and Prevalence of HPV 16/18 in Women with High-Grade Lesions (includes corresponding Graph/Chart)

Table 112. HPV Testing Market in Africa by Region (2014): Breakdown by No. of Women Tested and Prevalence of HPV 16/18 in Women with Cervical Cancer (includes corresponding Graph/Chart)

Table 113. Cervical Cancer Incidence in Africa by Region: 2012 (includes corresponding Graph/Chart)

Table 114. Estimated New Cervical Cancer Cases per Year in Africa by Region and Age Group: 2012 (includes corresponding Graph/Chart)

Table 115. Number of Deaths due to Cervical Cancer per Year in Africa by Region and Age Group: 2012 (includes corresponding Graph/Chart)

Table 116. Age-Standardized Cervical Cancer Incidence Rates in Africa by Region: 2012 (includes corresponding Graph/Chart)

Table 117. Age-Standardized Cervical Cancer Mortality Rates in Africa by Region: 2012 (includes corresponding Graph/Chart)

Product Launches
Strategic Corporate Developments
Key Players
B. Market Analytics

Table 118. Rest of World Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 119. Rest of World Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 43 (including Divisions/Subsidiaries - 48)
The United States (22)
Canada (2)
Europe (13)
  France (1)
  Germany (1)
  The United Kingdom (2)
  Italy (2)
  Rest of Europe (7)
Asia-Pacific (Excluding Japan) (11)